Protocol Ledger

NCT06659445 · Phase II · RECRUITING

Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

Interventional Phase II clinical trial protocol NCT06659445 sponsored by ONL Therapeutics in Ophthalmology and Sensory, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-10-28 Enrollment: 324 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06659445
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)324 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06659445
Protocol FieldVerified Registry Value
NCT IdentifierNCT06659445
Consolidated Lead SponsorONL Therapeutics
Therapeutic Condition CohortOphthalmology and Sensory
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment324 participants (ESTIMATED)
Registered Start Date2025-10-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06659445
Hospital Research SiteLocationSite Profile
California Retina ConsultantsBakersfield, CAOpen Hospital Dossier ->
Retina Vitreous Associates Medical GroupBeverly Hills, CAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Ophthalmology and Sensory Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI